2025
Sacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics
Adin M, Woolf G, Hegde R, Elsamadicy A, Mendel E, Zucconi W, Pucar D, Aygün N. Sacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics. Skeletal Radiology 2025, 1-26. PMID: 39821683, DOI: 10.1007/s00256-024-04862-6.Peer-Reviewed Original ResearchPrimary tumorTumor mimicsImaging findingsAssessment of response to treatmentGerm cell tumorsEvaluation of systemic diseasesResponse to treatmentInsufficiency fracturesSacral massSecondary tumorsCell tumorsPretreatment evaluationDiagnostic challengeLymphoproliferative diseaseClinical detailsMalignant tumorsPrimary modalitySystemic diseaseEwing sarcomaTumorNotochordal remnantsDevelopmental entityEpidemiological factorsDiagnosisMetastasis
2024
EIF1AX mutation in thyroid nodules: a histopathologic analysis of 56 cases in the context of institutional practices
Abi-Raad R, Xu B, Gilani S, Ghossein R, Prasad M. EIF1AX mutation in thyroid nodules: a histopathologic analysis of 56 cases in the context of institutional practices. Virchows Archiv 2024, 485: 859-867. PMID: 39225726, PMCID: PMC11912518, DOI: 10.1007/s00428-024-03914-5.Peer-Reviewed Original ResearchFollicular nodular diseaseAnaplastic thyroid carcinomaPapillary thyroid carcinomaEIF1AX mutationsBenign thyroid nodulesThyroid carcinomaThyroid nodulesOncocytic adenomasMolecular alterationsGenetic abnormalitiesNon-invasive follicular thyroid neoplasmPapillary-like nuclear featuresAssociated with malignant tumorsWHO 5th EditionCancer referral centerFollicular thyroid neoplasmTertiary care hospitalOncocytic carcinomaThyroid neoplasmsReferral centerNodular diseasePathological diagnosisCancer Genome AtlasMalignant tumorsEIF1AXLaryngeal rare benign non-epithelial tumors and sarcomas emphasizing on chondrosarcomas: A literature review and a case presentation
Vageli D, Doukas P, Paraskeva A, ZACHAROULI K, Judson B, IOANNOU M. Laryngeal rare benign non-epithelial tumors and sarcomas emphasizing on chondrosarcomas: A literature review and a case presentation. Pathology - Research And Practice 2024, 261: 155512. PMID: 39116572, DOI: 10.1016/j.prp.2024.155512.Peer-Reviewed Original ResearchRare tumorNon-epithelialLaryngeal chondrosarcomaMalignant tumorsMesenchymal originBenign non-epithelial tumorsNon-epithelial benign tumorsRare laryngeal tumorNon-epithelial tumorsHigh-grade tumorsLow-grade neoplasmsMesenchymal malignant tumorCases of LCMesenchymal entityRare malignancyEpithelial tumorsMesenchymal tumorsBenign tumorsS100 markersLaryngeal tumorsPrognostic markerLaryngeal malignanciesLaryngeal sarcomasPathological entitySarcoma Study
2023
Self‐Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma
Li Y, Zhao Q, Zhu X, Zhou L, Song P, Liu B, Tian D, Chen Q, Zhou J, Deng G. Self‐Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma. CNS Neuroscience & Therapeutics 2023, 30: e14528. PMID: 38044793, PMCID: PMC11017454, DOI: 10.1111/cns.14528.Peer-Reviewed Original ResearchBlood-brain barrierP-gp inhibitorsCerebral vascular endothelial cellsStrong anti-tumor effectsCommon primary malignant tumorApplication of paclitaxelEfflux transportersPrimary malignant tumorsUse of paclitaxelEfficacy of paclitaxelAnti-tumor effectsPeripheral solid tumorsCentral nervous systemNatural bioactive moleculesEffective anti-cancer drugsP-gp transporterVascular endothelial cellsBlood concentrationsMalignant tumorsGlioma treatmentNervous systemP-gpAnti-cancer drugsSolid tumorsTumor tissueComparison of the diagnostic efficiency between the O-RADS US risk stratification system and doctors’ subjective judgment
Zhou S, Guo Y, Wen L, Liu J, Fu Y, Xu F, Liu M, Zhao B. Comparison of the diagnostic efficiency between the O-RADS US risk stratification system and doctors’ subjective judgment. BMC Medical Imaging 2023, 23: 190. PMID: 37986051, PMCID: PMC10662783, DOI: 10.1186/s12880-023-01153-9.Peer-Reviewed Original ResearchThe Role of B Cells in Skin Inflammation
Frank A, Belperron A, Bockenstedt L. The Role of B Cells in Skin Inflammation. Journal Of Student Research 2023, 11 DOI: 10.47611/jsr.v11i3.1684.Commentaries, Editorials and LettersChapter 28 Fossa ovalis, patent foramen ovale, and cardiac masses
Nasir A, Zafar M, Elefteriades J. Chapter 28 Fossa ovalis, patent foramen ovale, and cardiac masses. 2023, 403-437. DOI: 10.1016/b978-0-323-84906-7.00013-3.Peer-Reviewed Original ResearchFossa ovalisPatent foramenCardiac massCardiac myxomaSeptum primumPlatypnea-orthodeoxia syndromePatent foramen ovaleArterial emboliCryptogenic strokeCertain disease conditionsNonneoplastic entitiesOstium secundumFat emboliForamen ovaleCardiac proceduresPulmonary circuitRight atriumInteratrial septumLeft heartMalignant tumorsSurgical significanceSystemic circulationSurgical planeIncomplete unionEmbryonic septum
2022
Pleomorphic Carcinoma Versus Sarcomatoid Malignant Mesothelioma
Baine M, Cai G, Zhang X. Pleomorphic Carcinoma Versus Sarcomatoid Malignant Mesothelioma. Practical Anatomic Pathology 2022, 137-145. DOI: 10.1007/978-3-031-14402-8_23.Peer-Reviewed Original ResearchSarcomatoid malignant mesotheliomaPleomorphic carcinomaMalignant mesotheliomaGiant cell carcinomaCell lung carcinomaSmall biopsy specimensPleural involvementPeripheral tumorsClinicopathologic featuresUpper lobeSarcomatoid morphologyCell carcinomaBiopsy specimensLung carcinomaLung parenchymaMalignant tumorsSpindle cellsAnatomic localizationChest wallCarcinomaGiant cellsMesotheliomaLungTumorsCellsRisk of Subsequent Central Nervous System Neoplasms in Childhood Cancer Survivors after Radiation Therapy: Results from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Collaboration
Casey D, Brodin P, Roberts K, Vogelius I, Avanzo M, Moni J, Owens C, Ronckers C, Constine L, Bentzen S, Olch A. Risk of Subsequent Central Nervous System Neoplasms in Childhood Cancer Survivors after Radiation Therapy: Results from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Collaboration. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s122-s123. DOI: 10.1016/j.ijrobp.2022.07.568.Peer-Reviewed Original ResearchSubsequent malignant tumorChildhood cancer survivorsMalignant CNS tumorsSubsequent meningiomaExcess odds ratioMalignant tumorsRadiation therapyCancer survivorsRT doseCNS tumorsOdds ratioHigh riskPediatric Normal Tissue EffectsPrior cranial radiation therapyCentral nervous system neoplasmsRadiation dose-response relationshipMalignant CNS tumorPrimary cancer diagnosisCranial radiation therapyNervous system neoplasmsIndependent patient cohortsDifferent dose intervalsNormal tissue effectsDose-response relationshipMATERIAL/METHODSHospital admission risks and ambient fine particulate matter exposure in Beijing, China
Wu Z, Liang F, Chen X, Liu G, Li G, Tian L, Guo Q, Yang C, Zhou Z, Pan X, Liu Y. Hospital admission risks and ambient fine particulate matter exposure in Beijing, China. Atmospheric Environment 2022, 288: 119291. DOI: 10.1016/j.atmosenv.2022.119291.Peer-Reviewed Original ResearchHospital admission riskMalignant tumorsRespiratory diseaseAllergic diseasesUrogenital diseasesPM2.5 exposureMetabolic diseasesMental disordersAdmission riskLong-term exposureAmbient fine particulate matter (PM2.5) exposureFine particulate matter exposureAmbient PM2.5 exposureLong-term PM2.5 exposureParticulate matter exposurePoisson regression modelsAmbient PM2.5 levelsIschemic strokeCirculatory diseasesMatter exposureHA riskAge groupsTumorsDiseaseSubgroup populationsUpdate of pathophysiology and treatment options of seborrheic keratosis
Gorai S, Ahmad S, Raza S, Khan H, Raza M, Etaee F, Cockerell C, Apalla Z, Goldust M. Update of pathophysiology and treatment options of seborrheic keratosis. Dermatologic Therapy 2022, 35: e15934. PMID: 36226729, DOI: 10.1111/dth.15934.Peer-Reviewed Original ResearchConceptsSeborrheic keratosisUpdate of pathophysiologyHuman papillomavirus infectionAmyloid-associated proteinsMale gender preponderanceYounger age groupsTerms of treatmentExpression of factorsPapillomavirus infectionPrecise pathogenesisTopical agentsGender preponderanceLocal anesthesiaTreatment optionsIndependent associationCosmetic concernsBenign tumorsMalignant tumorsCommon reasonAge groupsAlternative diagnostic techniquesFGFR-3Safe methodYoung adultsCosmetic purposesPatient-Derived Xenotransplant of CNS Neoplasms in Zebrafish: A Systematic Review
Sarmiento B, Callegari S, Ghotme K, Akle V. Patient-Derived Xenotransplant of CNS Neoplasms in Zebrafish: A Systematic Review. Cells 2022, 11: 1204. PMID: 35406768, PMCID: PMC8998145, DOI: 10.3390/cells11071204.Peer-Reviewed Original ResearchConceptsAssociated with poor survivalCentral nervous system tumorsNervous system tumorsCentral nervous system malignant tumorNeuro-oncology fieldPrimary cell culturesSystem malignant tumorResults of xenotransplantationCNS tumorsTumor microenvironmentSystem tumorsCNS neoplasmsMalignant tumorsTumor progressionPediatric populationPoor survivalTumorImprove outcomesCarcinogenic processMolecular genotypingSystematic reviewNeuroblastomaEffects of different treatmentsGlioblastomaZebrafish modelHepatic lymphatic vascular system in health and disease
Jeong J, Tanaka M, Iwakiri Y. Hepatic lymphatic vascular system in health and disease. Journal Of Hepatology 2022, 77: 206-218. PMID: 35157960, PMCID: PMC9870070, DOI: 10.1016/j.jhep.2022.01.025.Peer-Reviewed Original ResearchConceptsLiver diseaseNon-alcoholic fatty liver diseaseLymphatic systemFatty liver diseaseCongenital liver diseasesPotential therapeutic strategyHepatic lymphatic systemLiver transplantationPortal hypertensionMalignant tumorsTherapeutic strategiesDisease pathogenesisHepatic physiologyDiseasePathological conditionsSpecific markersLymphatic vesselsVascular systemLymphatic vascular systemOrgansTissue homeostasisHypertensionTransplantationPathophysiologyPathogenesis
2021
PATH-38. APC MUTATION AS A DRIVER ONCOGENE IN NON-CTNNB1 MUTANT ADAMANTINOMATOUS CRANIOPHARYNGIOMAS
Hong C, Erson-Omay Z, Omay S. PATH-38. APC MUTATION AS A DRIVER ONCOGENE IN NON-CTNNB1 MUTANT ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. Neuro-Oncology 2021, 23: vi123-vi123. PMCID: PMC8598823, DOI: 10.1093/neuonc/noab196.490.Peer-Reviewed Original ResearchAdamantinomatous craniopharyngiomaInstitutional review board-approved protocolCTNNB1 mutationsFamilial adenomatous polyposisWhole-exome sequencingAPC mutationsNeurological deficitsVentricular involvementOptic apparatusClassic subtypeStop codon mutationMalignant tumorsThird ventricleBRAF inhibitorsCraniopharyngeal ductDriver oncogenesTherapeutic strategiesMAP kinase/ERKCraniopharyngiomaGermline APC mutationsPapillary craniopharyngiomasPituitary glandAdenomatous polyposisPathogenic variantsEmbryonic remnantsA Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma
Kang R, Park J, Kim J, Chowdhury T, Oh J, Kim J, Shin J, Kim M, Park C, Lee S, Lee J, Kim D. A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma. ACS Biomaterials Science & Engineering 2021, 8: 4163-4174. PMID: 34196517, DOI: 10.1021/acsbiomaterials.1c00653.Peer-Reviewed Original ResearchConceptsDrug delivery systemsNanoparticle-based drug delivery systemsPolyethylene glycolHigher anticancer efficacyPorous silicon nanoparticlesDevelopment of nanotherapeuticsGlioblastoma multiformeSilicon nanoparticlesTetra peptideIRGD peptideTargeting abilityDelivery systemAnticancer efficacyNanoparticlesTherapeutic formulationsGreat promiseAggressive malignant tumorSite targetingNanotherapeuticsCell spheroidsPenetration abilityStructure specificityMalignant tumorsPenetration depthXenograft mice
2020
Convergent network effects along the axis of gene expression during prostate cancer progression
Charmpi K, Guo T, Zhong Q, Wagner U, Sun R, Toussaint N, Fritz C, Yuan C, Chen H, Rupp N, Christiansen A, Rutishauser D, Rüschoff J, Fankhauser C, Saba K, Poyet C, Hermanns T, Oehl K, Moore A, Beisel C, Calzone L, Martignetti L, Zhang Q, Zhu Y, Martínez M, Manica M, Haffner M, Aebersold R, Wild P, Beyer A. Convergent network effects along the axis of gene expression during prostate cancer progression. Genome Biology 2020, 21: 302. PMID: 33317623, PMCID: PMC7737297, DOI: 10.1186/s13059-020-02188-9.Peer-Reviewed Original ResearchConceptsHigh-throughput genomic measurementsProstate cancer progressionGene expressionMolecular networksCopy number alterationsCancer progressionComplex genomic alterationsTumor phenotypePrediction of recurrence-free survivalGenomic measurementsRecurrence-free survivalProstate cancer patientsProteomic alterationsGenomic aberrationsAggressive tumor phenotypeGenomic alterationsDownstream proteinsGenomic effectsNetwork-based approachProstate samplesTumor siteBiochemical stateMalignant tumorsProtein levelsTumor tissuesExpression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions
Chen PH, Bossuyt V, Reisenbichler E. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions. Human Pathology 2020, 108: 68-75. PMID: 33245988, DOI: 10.1016/j.humpath.2020.11.009.Peer-Reviewed Original ResearchConceptsMalignant phyllodes tumorPhyllodes tumorBenign tumorsLymphoid enhancer-binding factor 1Fibroepithelial lesionsTissue microarrayEnhancer-binding factor 1LEF-1 expressionMalignant tumorsBorderline/malignant phyllodes tumorsΒ-cateninStromal componentsNuclear expressionWorld Health Organization criteriaMetastatic phyllodes tumorWnt/β-catenin pathway activationAlternative treatment optionBorderline phyllodes tumorWnt/β-catenin pathwayFactor 1Β-catenin pathway activationE-cadherin immunohistochemistryWnt/β-catenin signalingΒ-catenin pathwayNuclear β-catenin stainingCholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 2020, 17: 557-588. PMID: 32606456, PMCID: PMC7447603, DOI: 10.1038/s41575-020-0310-z.Peer-Reviewed Original ResearchConceptsPrimary liver cancerExpert consensus statementCancer-related deathCell of originBiliary malignant tumorsStudy of CholangiocarcinomaGastrointestinal malignanciesHistological confirmationAvailable therapiesBiliary treeNew diagnostic toolsSilent presentationPatient outcomesConsensus statementMalignant tumorsLiver cancerCholangiocarcinomaAggressive natureAlarming mortalityCurrent diagnosisMolecular alterationsNon-invasive approachTumorsDiagnostic toolTherapy
2019
The use of cell free DNA in the diagnosis of HCC
Banini BA, Sanyal AJ. The use of cell free DNA in the diagnosis of HCC. Hepatoma Research 2019, 2019: 34. PMID: 31673629, PMCID: PMC6822275, DOI: 10.20517/2394-5079.2019.30.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDiagnosis of HCCHepatocellular carcinomaNon-invasive biomarkersCommon malignant tumorPotential clinical utilityCell-free nucleic acidsTypes of cancerCell-free DNALiquid biopsy analysisAnalysis of bloodLiver biopsyPeripheral bloodTumor recurrenceMalignant tumorsProstate cancerEarly diagnosisClinical utilityBiopsy analysisAdvanced stageHigh mortalityTreatment monitoringLiquid biopsyDiagnosisBody fluidsBiopsyPain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1
Buono FD, Grau LE, Sprong ME, Morford KL, Johnson KJ, Gutmann DH. Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1. Journal Of Pain Research 2019, 12: 2555-2561. PMID: 31692483, PMCID: PMC6710538, DOI: 10.2147/jpr.s209540.Peer-Reviewed Original ResearchNeurofibromatosis type 1Pain severityPain symptomsType 1Potential adverse side effectsPrescription pain medicationAdverse side effectsTreatment of peopleMedication dependenceOpioid medicationsPain medicationPain managementPain symptomatologyCurrent treatmentMalignant tumorsPain dataSurgical proceduresComplementary treatmentHigh incidenceAlternative treatmentSide effectsCareful monitoringMedicationsDaily functioningInitiative database
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply